(Total Views: 804)
Posted On: 07/16/2020 5:26:33 PM
Post# of 153875
Two HIV competitors: lencapravir and Cabo/Rilpi
Thanks much to viridi for this info. Maybe someone can help me out with questions I have.
Lencapravir is a capsid assembly/disassembly blocker in phase 1 human trials from Gilead which is dosed once every six months.
Gilead put up a poster presentationon lencapravir this past AIDS:2020 Virtual July 6-10.
I can't find the poster presentation. Anyone have access?
Gilead press release from July 2 says lencapravir is used in conjunction with arntiviras so I am not sure if lencapravir is intended as a montherapy. Also not sure if lencapravir will reduce HAART side effects. Also not sure about lencapravir side effects. Probably all are addressed in the recent AIDS:2020 Virtual poster presentation but I cant find that poster presentation.
Next up is Roche's Cabotegravir/Riolivirine. Cabo/Rilpi is a monthly or every two months injectable that is essentially the same as standard HAART, I think. So no reduction in HAART side effects, I think.
For all new drugs patient compliance is a key issue. Both lemapravir and cabo/rilpi have potential compliance advantages vs. daily HAART dosing and weekly leronlimab dosing.
However, a missed leronlimab dose may be of less importance than a missed lencapravir or cabo/rilpi dose.
Thanks much to viridi for this info. Maybe someone can help me out with questions I have.
Lencapravir is a capsid assembly/disassembly blocker in phase 1 human trials from Gilead which is dosed once every six months.
Gilead put up a poster presentationon lencapravir this past AIDS:2020 Virtual July 6-10.
I can't find the poster presentation. Anyone have access?
Gilead press release from July 2 says lencapravir is used in conjunction with arntiviras so I am not sure if lencapravir is intended as a montherapy. Also not sure if lencapravir will reduce HAART side effects. Also not sure about lencapravir side effects. Probably all are addressed in the recent AIDS:2020 Virtual poster presentation but I cant find that poster presentation.
Next up is Roche's Cabotegravir/Riolivirine. Cabo/Rilpi is a monthly or every two months injectable that is essentially the same as standard HAART, I think. So no reduction in HAART side effects, I think.
For all new drugs patient compliance is a key issue. Both lemapravir and cabo/rilpi have potential compliance advantages vs. daily HAART dosing and weekly leronlimab dosing.
However, a missed leronlimab dose may be of less importance than a missed lencapravir or cabo/rilpi dose.
(0)
(0)
